Can We Kill Two Birds with This Stone? Anti-Pneumocystis Prophylaxis to Prevent Nocardia Infection in Hematopoietic Stem Cell Transplant Recipients

Coussement, Julien; Greef, Julien De; Dureault, Amélie; Lebeaux, David

doi:10.1016/j.bbmt.2018.05.028

Cited by 3 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the assumptions raised by Molina et al [2] have been criticized by other experts. Interestingly, in this report most cases occurred during a certain period of time, thus raising the possibility of an airborne Nocardia outbreak [3]. Although infection due to Nocardia occurs sporadically, several previous reports have raised the possibility of Nocardia outbreaks affecting bone marrow transplant units [4].…”

Section: To the Editormentioning

confidence: 64%

Low-Dose Cotrimoxazole Administered in Hematopoietic Stem Cell Transplant Recipients as Prophylaxis for Pneumocystis jirovecii Pneumonia Is Effective in Prevention of Infection due to Nocardia

Gkirkas

Stamouli

Thomopoulos

et al. 2019

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Section: To the Editormentioning

confidence: 64%

Low-Dose Cotrimoxazole Administered in Hematopoietic Stem Cell Transplant Recipients as Prophylaxis for Pneumocystis jirovecii Pneumonia Is Effective in Prevention of Infection due to Nocardia

Gkirkas

Stamouli

Thomopoulos

et al. 2019

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Pulmonary infections in the hematopoietic cell transplant patient

Ford

Crothers

Cheng

2020

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of review Despite progress in the management of pulmonary infections in the hematopoietic cell transplant (HCT) population, substantial diagnostic, and therapeutic uncertainty remains. Recent findings A growing HCT population reflects more transplants and improved long-term survival. We continue to learn about the epidemiologic and prognostic significance of posttransplant pulmonary infections. Mold-active triazoles have removed invasive fungal pneumonia as a barrier to transplant eligibility. Ibrutinib and respiratory viruses are newly recognized risk factors for invasive fungal disease. Prophylaxis has elevated concerns of resistance in invasive fungal species and late onset Cytomegalovirus. The impact of human herpesviruses, community-associated respiratory viruses, and the microbiome is increasingly appreciated. Multiple antiviral therapies are currently in clinical trials and novel molecular diagnostics may improve the performance of bronchoscopy for infectious causes. Summary Fungal and viral pneumonias remain an important cause of morbidity and mortality in the HCT population. Despite our increased understanding of the epidemiology and outcomes of species-specific diagnoses, the utility of invasive diagnostic testing continues to be debated and effective therapies for many clinically relevant pathogens remain limited. Pulmonary infections are a priority for research efforts in this immunocompromised population.

show abstract